Posters

Quality of life in glaucoma patients and normal subjects related to the severity of damage in each eye

Poster Details

First Author: O. Pujol SPAIN

Co Author(s):    M. Ana   A. Jorge   A. Eleonora   M. Clara   A. Alfonso        

Abstract Details

Purpose:

To assess the quality of life (QoL) in glaucoma patients and normal subjects, and to assess its relation with the severity of damage in each eye

Setting:

Hospital de l´Esperança-Parc de Salut Mar. Barcelona.

Methods:

Three hundred and fifty nine subjects were included and divided in three categories. Group 1 had both eyes normal. Group 2 comprised 81 patients with both eyes with mild or moderate glaucoma. Group 3 included 70 patients with moderate to severe glaucoma in both eyes. Group 4 included 61 patients with asymmetric glaucomatous damage: one eye with severe glaucoma and the other eye normal or with mild glaucoma. All subjects completed 3 different questionnaires: EuroQol-5D (EQ-5D), Visual Function Questionnaire (VFQ-25) and Ocular Surface Disease Index (OSDI).

Results:

VFQ-25 showed that group 1 and 4 had less difficulties than group 3 with distance activities (88,2 ±17,2; p= 0,017 and 89,14±15,6;p= 0,027, respectively), social function (93,6±15,3; p= 0,009 and 94,87±13,4; p= 0,011, respectively) and color vision (94,5±15,3; p= 0.022 and 95,54±14,3;p=0,027, respectively). Additionally, group 1 had less difficulties or higher punctuation than group 3 in near activities (85,5 ±20,02; p=0,006), peripheral vision (91,75 ± 19,8; p= 0,012) and general vision (71,4±15,3; p=0.01). In terms of global QoL, group 4 obtained a higher score (73,21±16,6) than all other groups (all, p<0,05). QoL related to ocular surface disease did not show significant differences among the groups (all, p>0,05).

Conclusions:

Patients with severe glaucoma in both eyes had worse QoL, or more difficulties performing different every day activities than patients with mild or asymmetric glaucomatous damage. No significant differences were found between asymmetric glaucomas and patients with normal or mild glaucomas in both eyes.

Financial Disclosure:

NONE